🟢 Compass Pathways is trading 5.2% up today after positive 52-week COMP005 trial results

Compass Pathways is trading at $14.78, up +5.24%, after announcing positive 52-week topline results from Part C of its Phase 3 COMP005 trial on September 9, 2026.

• The 25 mg group receiving an additional COMP360 dose achieved an average 13-point MADRS reduction at Week 52, extending durability to one year.
• Response and remission rates were encouraging, with no new safety concerns reported.
• The company’s September 9 Cantor conference appearance may provide additional investor attention.